RBBP8 and urinary bladder carcinoma: Accordingly, RBBP8 methylation significantly discriminates between bladder cancer patients and non-malignant patients with a sensitivity of 51.9% and a specificity of 90.9% (AUC 0.730, 95% CI 0.616–0.844) (Fig. 7b).